Alkermes claims ALKS 8700 success; third pipeline win in 2015
This article was originally published in Scrip
Alkermes plans to move ALKS 8700, a novel monomethyl fumarate (MMF) molecule and a competitor for Biogen Idec's successful oral multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate), into pivotal studies following a large, placebo-controlled Phase I clinical trial.
You may also be interested in...
ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.